Takeda, DNDi to Collaborate in Visceral Leishmaniasis Drug Development

April 6, 2018
Takeda Pharmaceutical and Geneva-based nonprofit Drugs for Neglected Diseases initiative (DNDi) said on April 5 that they have inked a new agreement to forge ahead with the development of candidate compounds they have identified for the treatment of visceral leishmaniasis...read more